Tyrus Rorick

Duke University — United States

Medicine · Health Sciences

11h-index1.8kcitations15works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antiplatelet Therapy and Cardiovascular Diseases(9), Atrial Fibrillation Management and Outcomes(6), Acute Myocardial Infarction Research(6), Health Systems, Economic Evaluations, Quality of Life(5), Lipoproteins and Cardiovascular Health(3)

Publications13 total

Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials
JAMA Network Open·2021· 10 citedOpen Access
The use of electronic health records for recruitment in clinical trials: a mixed methods analysis of the Harmony Outcomes Electronic Health Record Ancillary Study
Trials·2021· 23 citedOpen Access
Good Clinical Practice Guidance and Pragmatic Clinical Trials
Circulation·2016· 120 citedOpen Access
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
American Heart Journal·2014· 409 citedOpen Access
PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact
Platelets·2014· 23 cited
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes
Thrombosis and Haemostasis·2014· 30 cited
Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)
The American Journal of Cardiology·2013· 18 cited
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial
European Heart Journal·2013· 37 cited
PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL
Journal of the American College of Cardiology·2012
REDUCTION OF MYOCARDIAL INFARCTION WITH VORAPAXAR: RESULTS FROM THE TRA·CER TRIAL
Journal of the American College of Cardiology·2012
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
New England Journal of Medicine·2011· 747 citedOpen Access
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
Contemporary Clinical Trials·2011· 16 cited
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA center dot CER) Trial
Circulation·2011

Frequent Co-authors

Pierluigi Tricoci(9), Kenneth W. Mahaffey(9), Robert A. Harrington(8), John Strony(7), David J. Moliterno(6), Paul W. Armstrong(6), Edmond Chen(6), Claes Held(5), Frans Van de Werf(5), Philip E. Aylward(5), Sergio Leonardi(5), Robert F. Storey(5), Lisa G. Berdan(5), Harvey D. White(4), Lars Wallentin(4), Lisa K. Jennings(4), Zhen Huang(3), Jan H. Cornel(3), Kurt Huber(3), Marco Valgimigli(3)